JYJun Yamagami

Jun Yamagami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun Yamagami has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immune Responses Associated With Nephritis‐Associated Plasmin Receptor in IgA Vasculitis

    by Suguru Yoshida, Ryujin Miyata, Tamaki Matsumoto, Yoshishige Miyabe, Takashi Oda, Kazuo Yudoh, Naoko Ishiguro, Jun Yamagami, Chie Miyabe

    IgA vasculitis (IgAV), formerly known as Henoch‐Schönlein purpura, is a small‐vessel vasculitis characterized by IgA‐dominant immune deposits in the skin, kidney, gastrointestinal tract, and joints, often following infections, particularly β‐hemolytic streptococci. Nephritis‐associated plasmin receptor (NAPlr), a streptococcal glyceraldehyde‐3‐phosphate dehydrogenase, has been identified as a nephritogenic protein in post‐streptococcal acute glomerulonephritis, binding plasmin and maintaining its proteolytic activity, thereby promoting tissue injury. However, the role of NAPlr in IgAV pathophysiology remains unclear. In this study, we investigated histological staining for NAPlr and plasmin activity in IgAV cutaneous lesions and evaluated circulating anti‐NAPlr antibodies. Skin specimens from patients with IgAV were analyzed by immunofluorescence and in situ zymography, and serum anti‐NAPlr antibodies (IgG, IgM, and IgA) were measured by enzyme‐linked immunosorbent assay in 21 patients with IgAV and 18 healthy donors. Positive staining for NAPlr and plasmin activity was observed in dermal lesions in 7 of 11 patients with IgAV, but was minimal in control skin. Patients with IgAV showed significantly elevated serum levels of anti‐NAPlr IgG and IgA antibodies compared with healthy donors. Anti‐NAPlr IgG levels positively correlated with serum creatinine and negatively correlated with CH50, with a nonsignificant inverse association with estimated glomerular filtration rate (eGFR). Serum galactose‐deficient IgA1 levels were also significantly increased in patients with IgAV, and were positively correlated with anti‐NAPlr IgA levels but negatively correlated with C4. These findings demonstrate the presence of a protein that is stained by anti‐NAPlr antibody in IgAV cutaneous lesions alongside elevated circulating anti‐NAPlr antibodies, suggesting that immune responses to NAPlr may contribute to IgA‐mediated vascular inflammation, potentially through complement activation.

  • Open Access

    Development of a digital image analysis system for objective evaluation of treatment response in cellulitis

    by Kazunori Miyata, Jun Yamagami, Yuko Takenaka, Mai Onuki, Tomoaki Sawayanagi, Naoko Ishiguro

    Cellulitis is a common skin infection. While changes in lesion color are valuable indicators of treatment efficacy, assessments often rely on subjective judgments. To provide an objective method for evaluating treatment response, we developed a digital imaging system that quantifies red, green, and blue (RGB) values of lesions and calculates the RGB distance between lesions and normal skin. We analyzed 34 patients with cellulitis treated between 2022 and 2025. Clinical images were obtained on days 1 (baseline), 3, 7, and 14. By day 14, the G and B values of lesions increased significantly (G: 115.6 to 135.7, B: 91.8 to 105.5; P < 0.05), while the R values remained stable. The RGB distance decreased significantly from day 3 (64.3 to 53.7; P < 0.05). Patients were classified by Investigator's Global Assessment into Group A (favorable clinical outcome, n = 13) and Group B (delayed clinical improvement, n = 21). Receiver operating characteristic analyses of the RGB distance ratio relative to day 1 showed high accuracy at day 3 (cut-off = 0.62) and day 7 (cut-off = 0.48). A significantly higher proportion of Group B patients had a history of edema. These findings suggest our system provides an objective method for evaluating the clinical course of cellulitis.

  • Top Cited Papers

    Conversion of pathogenic T cells into functionally stabilized T reg cells for antigen-specific immunosuppression in pemphigus vulgaris

    by Miho Mukai, Hayato Takahashi, Yoko Kubo, Yasuhiko Asahina, Hisato Iriki, Hisashi Nomura, Aki Kamata, Hiromi Ito, Yutaka Kurebayashi, Jun Yamagami, et al.

    Antigen-specific immunotherapy represents one candidate strategy for treating autoimmune diseases such as pemphigus vulgaris, a skin autoimmune disorder mediated by anti–desmoglein 3 (Dsg3) autoantibodies. We developed a therapeutic strategy by which Dsg3-specific pathogenic autoreactive CD4 + T cells were converted in vitro into functionally stable Foxp3 + regulatory T (T reg ) cells, designated stable and functional induced T reg (S/F-iT reg ) cells. The conversion was achieved by pharmacological induction of Foxp3 and costimulation-dependent installation of T reg cell–specific epigenetic changes. In an animal model of pemphigus vulgaris, the Dsg3-specific S/F-iT reg cells expanded specifically in the skin-draining lymph nodes through recognition of endogenous Dsg3. They selectively inhibited Dsg3-specific T follicular helper cell and B cell proliferation and, consequently, anti-Dsg3 autoantibody formation, without affecting the total B cell population, thereby mitigating disease progression without inducing systemic immunosuppression. Human S/F-iT reg cells with similar functions could also be efficiently generated from peripheral blood T cells of patients with pemphigus vulgaris. This study demonstrates that pathogenic autoreactive T cells can be converted into disease-specific T reg cells retaining antigen specificity, enabling antigen- and disease-specific treatment of autoimmune disease.


  • Open Access

    Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnaires

    by Chika Tanemura, Maya Nunotani, Kyoko Kawabata, Yuki Morooka, Jun Yamagami, Risa Kakuta, Yasuko Saito, Yuichi Kurihara, Hayato Takahashi, Norito Ishii, et al.

    Patients with autoimmune bullous disease have their quality of life (QOL) affected by both the disease and its treatment burden. While QOL assessment is clinically important, it is often hindered by limited time in clinical practice, highlighting the need for accurate and efficient QOL evaluation tools. However, no validated QOL questionnaires are currently available in Japan. This study evaluated the validity and reliability of the Japanese versions of the Autoimmune Bullous Disease Quality of Life (ABQOL) and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires, as well as their practical application in clinical settings. The original questionnaires were forward and back‐translated into Japanese by certified translators according to established guidelines, then their validity and reliability were evaluated using data from 147 patients with autoimmune bullous diseases. Validity was evaluated via confirmatory and exploratory factor analyses, cross‐cultural validation, hypothesis testing, and convergent validity. Reliability was evaluated via test–retest and internal consistency. Although confirmatory factor analysis showed a weak fit and factor structures slightly differed from the original versions, internal consistency was cross‐culturally valid. Also, the Japanese version cohort showed lower mean scores and better QOL outcomes compared with other language versions for similar cohorts. Hypothesis testing revealed a significant positive correlation between ABQOL scores and subjective disease severity; TABQOL scores were significantly correlated with steroid dosage. The mucosal subscale of the ABQOL showed a significant difference based on mucosal lesion status. Bland–Altman plots confirmed approximate agreement between the two sets of measurements: Cronbach's alpha coefficients were 0.872 for ABQOL and 0.903 for TABQOL, verifying reliability. Finally, an expert panel reviewed and agreed on the target population, timing, methods for using the scales, and considerations for scale evaluation. The Japanese versions of the ABQOL and TABQOL are expected to be implemented in clinical practice as reliable and validated tools in Japan.


  • Author Correction: Bullous pemphigoid

    by Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, Yen Loo Lim, Anisa Mosam, Kaisa Tasanen, Jun Yamagami, Maryam Daneshpazhooh, Dipankar De, Adela Rambi G. Cardones, et al.


  • Top Cited Papers

    Bullous pemphigoid

    by Hossein Akbarialiabad, Enno Schmidt, Aikaterini Patsatsi, Yen Loo Lim, Anisa Mosam, Kaisa Tasanen, Jun Yamagami, Maryam Daneshpazhooh, Dipankar De, Adela Rambi G. Cardones, et al.

    Bullous pemphigoid is a chronic, subepidermal autoimmune blistering disease characterized by tense blisters on erythematous or normal skin that predominantly affects the older population. The disease arises from autoantibodies targeting hemidesmosomal proteins BP180 and BP230, which are crucial for dermal–epidermal adhesion. The incidence of bullous pemphigoid is increasing, attributed to an ageing population and improved diagnostic recognition. Genetic predisposition, environmental triggers and associations with other autoimmune disorders underline its multifactorial nature. Diagnosis involves clinical presentation, histopathology, direct immunofluorescence and serological tests. Treatment aims to reduce symptoms and prevent new blister formation, using corticosteroids, immunosuppressive agents and biologics such as rituximab and omalizumab. Despite therapeutic advancements, challenges persist in long-term management, especially in older patients with comorbidities. Ongoing research into molecular mechanisms and novel therapeutic targets and clinical trials are crucial for the development of safer and more effective treatments.


  • Open Access

    Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece

    by Meropi Karakioulaki, Patrick Dunn, Dedee F. Murrell, Aimee Payne, Enno Schmidt, Victoria Werth, Marc Yale, Jun Yamagami, Valeria Aoki, Luca Borradori, et al.


  • Open Access

    B‐cell targeted therapy of pemphigus

    by Jun Yamagami

    Pemphigus is an autoimmune disease that causes blistering and erosion of the skin and mucous membranes because of autoantibodies against desmoglein, which plays an important role in adhesion between epidermal keratinocytes. Treatment of pemphigus has long been centered on corticosteroids, and the guidelines for management of pemphigus have recommended high‐dose systemic corticosteroids as the first‐line treatment. While guideline‐based treatment has been shown to be beneficial in patients with pemphigus, it has also become clear that this treatment is accompanied by significant burden and risk. The challenge for future pemphigus treatment is to maximize efficacy while minimizing risk during the course of the disease. In this regard, treatment targeting B cells is expected to become increasingly important as autoreactive B cells in pemphigus patients are thought to play a major role in the production of autoantibodies, which form the basis of the pathogenesis. The recent expansion of insurance coverage to rituximab, a monoclonal antibody against CD20, for refractory pemphigus in the USA, Europe, and Japan has opened up a new era of pemphigus treatment by enabling treatment strategies with drugs targeting B cells in patients. Here, we discuss the current status and future prospects of pemphigus treatment, focusing on rituximab and Bruton's tyrosine kinase inhibitors, which are expected to become essential drugs for pemphigus treatment in the future.


  • Open Access

    Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients

    by Jun Yamagami, Yuichi Kurihara, Takeru Funakoshi, Yasuko Saito, Ryo Tanaka, Hayato Takahashi, Hideyuki Ujiie, Hiroaki Iwata, Yoji Hirai, Keiji Iwatsuki, et al.

    This was a multicenter clinical trial of rituximab, a chimeric monoclonal IgG antibody directed against CD20, for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. In total, 20 patients were treated with two doses of rituximab (1000 mg; 2 weeks apart) on days 0 and 14. The primary end point was the proportion of patients who achieved complete or partial remission on day 168 following the first rituximab dose. Of the 20 enrolled patients, 11 (55%) and four (20%) achieved complete and partial remission, respectively; therefore, remission was achieved in a total of 15 patients (75.0% [95% confidence interval, 50.9%–91.3%]). It was demonstrated that the remission rate was greater than the prespecified threshold (5%). In addition, a significant improvement in clinical score (Pemphigus Disease Area Index) and decrease in serum anti‐desmoglein antibody level were observed over time. Four serious adverse events (heart failure, pneumonia, radial fracture, and osteonecrosis) were recorded in two patients, of which only pneumonia was considered causally related with rituximab. The level of peripheral blood CD19‐positive B lymphocytes was decreased on day 28 after rituximab treatment and remained low throughout the study period until day 168. Our results confirm the efficacy and safety of rituximab therapy for refractory pemphigus in Japanese patients.